Cancer Type/Condition: Lymphoma, Hodgkin lymphoma, adult
Stage/Subtype: stage II adult Hodgkin lymphoma
Country: U.S.A.
Trial Type: Treatment
Trial Status: Active
1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MSKCC-95024, NCI-V95-0685, NCT00002663
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CY 2121, NCT00343564
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: J0703, NA00005743, NCT00484874
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 0 to 55
Sponsor: Other
Protocol IDs: 8717, NCT00673114
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-0403, NCT00724984
|
|
8.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 74
Sponsor: NCI
Protocol IDs: 080051, 08-C-0051, NCT00923910
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: SUMC-G5, NCI-V01-1671, NCT00026208
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-02-C-0284, NCI-5744, NCT00047164, 5744
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: NCI
Protocol IDs: UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
|
|
12.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: JHOC-J0615, J0615, JHOC-NA_00002473, NCT00369681
|
|
13.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
14.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 2 and over
Sponsor: NCI
Protocol IDs: CHNMC-06141, 06141, NCT00589563
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 11300A, NCT00683046
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPKC412D2201, NCT00782067
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 and over
Sponsor: Other
Protocol IDs: UFPTI 0806 - HL01, NCT00850200
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 70
Sponsor: NCI, NHLBI
Protocol IDs: 606, U01 HL069294, NCT00864227
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P2 L-D AB, NCT00917826
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 09-0679-04, NCT00997386
|
|
21.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 65
Sponsor: Other
Protocol IDs: 2009-0266, NCT01010217
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 0C-07-6, NCT00630760
|
|
23.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: BCM-H-9936-ALCI, H 9936, NCT00671164
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BB-IND 13254, NCT00672152
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 22899, NCT00709033
|
